The novel antagonists 73 and 100 demonstrated gene-specific effects in LS174T colorectal cancer cells, not inducing on their own the expression of ABCB1, but inducing CYP3A4 expression to a similar extent as rifampicin. The gene discussed is CYP3A4; the disease is colorectal cancer.